Exercise of Warrants and Issue of Equity
Hemogenyx Pharmaceuticals announced the receipt of warrant exercises for 67,371 new ordinary shares, generating subscription monies of £235,799 for the company. Application has been made for these shares to be admitted to the FCA official list, with trading expected to commence around 8:00 a.m. on September 10, 2025. Following admission, the total number of issued shares and voting rights will be 5,361,267, including the 250,000 new ordinary shares issued as announced on September 3, 2025. This figure should be used by shareholders to calculate their notification requirements regarding their interest in the company's share capital under FCA rules.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 67,371 new ordinary shares in the Company (the "Warrant Shares").
The Warrant Shares are being issued pursuant to the exercise of warrants granted and announced on 11 March 2025. Subscription monies of £235,799 have been received by the Company in respect of the exercise.
Admission and Total Voting Rights
Application will be made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 10 September 2025 ("Admission").
Upon Admission (and including the 250,000 new ordinary shares being issued as announced on 3 September 2025), the total number of issued shares and the total number of voting rights in the Company will be 5,361,267.
The above figure of 5,361,267 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.